Eczema and atopic dermatitis improvement
EPO's GLA content corrects the documented delta-6-desaturase enzyme deficiency in atopic dermatitis patients, restoring normal GLA and dihomo-GLA (DGLA) levels in skin lipids. Clinical studies show improvements in eczema severity, itching, scaling, and skin barrier function — with effects most pronounced in children with severe atopic dermatitis.
PMS and mastalgia relief
GLA-derived prostaglandin E1 (PGE1) has potent anti-inflammatory and pain-modulating effects in breast tissue. Clinical studies show EPO reduces cyclical breast pain (mastalgia) severity and reduces overall PMS symptom burden — particularly physical symptoms — through PGE1-mediated reduction of breast tissue prostaglandin F2α-driven inflammation.
Diabetic peripheral neuropathy improvement
Multiple clinical studies show GLA supplementation from EPO improves nerve conduction velocity, reduces neuropathic pain, and improves neurological assessments in diabetic neuropathy patients — attributed to GLA's role in restoring normal nerve membrane lipid composition and improving endoneurial blood flow.
Rheumatoid arthritis symptom reduction
EPO supplementation (at GLA doses of 1.4–2.8 g/day) significantly reduces morning stiffness, joint tenderness, and overall disease activity in rheumatoid arthritis patients. The anti-inflammatory prostaglandin E1 pathway provides complementary effects to NSAIDs and DMARDs.
Delta-6-desaturase bypass and DGLA production
Dietary linoleic acid (LA) normally requires delta-6-desaturase to convert to GLA — a step that is rate-limited and impaired in atopic, diabetic, and inflammatory conditions. GLA from EPO bypasses this bottleneck, providing direct substrate for conversion to DGLA and then to anti-inflammatory PGE1 — restoring normal eicosanoid balance without requiring the deficient enzyme.
Prostaglandin E1 synthesis and anti-inflammatory activity
DGLA (from GLA) is converted by COX-1/2 to prostaglandin E1 (PGE1) and 15-HETrE — eicosanoids with potent anti-inflammatory, vasodilatory, and platelet-inhibiting properties. PGE1 specifically opposes the inflammatory prostaglandin E2 and thromboxane A2 pathways — providing a natural anti-inflammatory mechanism that complements but is distinct from COX inhibition.
Skin barrier lipid restoration
GLA is incorporated into ceramide and phospholipid structures in the epidermal lipid barrier. In eczema patients with deficient delta-6-desaturase activity, topical and oral GLA supplementation restores normal skin lipid composition, reducing transepidermal water loss and improving the barrier function that prevents allergen penetration and inflammatory activation.
Meta-analysis of 9 clinical studies examining EPO for atopic eczema in children and adults.
Pooled data from 9 studies in atopic eczema patients.
EPO significantly improved itch severity, scaling, and overall eczema severity in most studies. Effects stronger in studies with longer duration and higher GLA doses. Children showed larger improvements than adults. Supports EPO as adjunct for atopic dermatitis, particularly in children.
Randomized, double-blind, placebo-controlled trial of GLA (480 mg/day from EPO) vs. placebo in 111 diabetic neuropathy patients for 1 year.
111 diabetic patients with confirmed peripheral neuropathy. 1-year intervention.
GLA significantly improved all 16 outcome measures including nerve conduction velocity, thermal thresholds, sensory perception, and neurological assessment scores. All improvements statistically significant at 1 year. Supports GLA as effective diabetic neuropathy intervention.